 "anti obesity drugs, weight loss")
As global demand for next-generation therapies on diabetes and weight loss surges, Indian pharmaceutical companies are gearing up to roll out generic versions of semaglutide once its patent expires around March next year.
Semaglutide is a GLP-1 (glucagon-like peptide 1) receptor agonist that is used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. The generic launches will be significant because the prices for the Indian consumer are expected to come down significantly from the current ₹17,000-26,000 (monthly), expanding patient coverage.
Dr Reddy’s Laboratories (DRL), Cipla, Sun Pharma, and Mankind Pharma, among others, are laying the
